HISTORY

Nearly 30 years of development and partnership

Nearly 30 years of development and partnership

For nearly three decades, MorphoSys has been devoted to discovering and developing promising novel therapies for some of the world’s most serious diseases.

Our story began with a specific technology that first positioned us as invaluable pharmaceutical partners—and then empowered our evolution into a fully integrated biopharmaceutical company.

For more about our history, visit morphosys.com/company/history

MorphoSys Logo

1992

Founded by Managing Director Simon Moroney in Munich, Germany

1993-2011

Advancing antibody science to develop novel and innovative approaches to treating cancer

1997-2017

Developed licensing agreements with partners including Novartis, Janssen, and Pfizer

Since 2007

Developing proprietary drug candidates through partnerships with GSK, Xencor, and I-Mab Biopharma, among others

2018

Nasdaq IPO and establishment of MorphoSys US Inc.

2019

Appointed Jean-Paul Kress CEO; established US subsidiary in Boston, with David Trexler as President of MorphoSys US

December 2019

Submission of Biologics License Application for tafasitamab-cxix in R/R DLBCL to the FDA

January 2020

MorphoSys and Incyte sign Global Collaboration and License Agreement for tafasitamab-cxix

February 2020

MorphoSys initiates Expanded Access Program for tafasitamab-cxix in the US

March 2020

MorphoSys receives Priority Review of its biologics license application (FDA, US)

July 2020

FDA approves MONJUVI® (tafasitamab-cxix)